2. Academic Validation
  3. Evaluation of the anti-tumor effects of lactate dehydrogenase inhibitor galloflavin in endometrial cancer cells

Evaluation of the anti-tumor effects of lactate dehydrogenase inhibitor galloflavin in endometrial cancer cells

  • J Hematol Oncol. 2015 Jan 29;8:2. doi: 10.1186/s13045-014-0097-x.
Xiaoyun Han 1 2,  Xiugui Sheng 3,  Hannah M Jones 4,  Amanda L Jackson 5,  Joshua Kilgore 6,  Jessica E Stine 7,  Monica N Schointuch 8,  Chunxiao Zhou 9 10,  Victoria L Bae-Jump 11 12
Affiliations

Affiliations

  • 1 Department of Gynecologic Oncology, ShanDong Cancer Hospital & Cancer Institute, Jinan, 250117, P.R China. xiaoyun_han@med.unc.edu.
  • 2 Division of Gynecologic Oncology, University of North Carolina at Chapel Hill, CB# 7572, Physicians Office Building Rm# B105, Chapel Hill, NC, 27599, USA. xiaoyun_han@med.unc.edu.
  • 3 Department of Gynecologic Oncology, ShanDong Cancer Hospital & Cancer Institute, Jinan, 250117, P.R China. shengxiugui@163.com.
  • 4 Division of Gynecologic Oncology, University of North Carolina at Chapel Hill, CB# 7572, Physicians Office Building Rm# B105, Chapel Hill, NC, 27599, USA. hannah_jones@med.unc.edu.
  • 5 Division of Gynecologic Oncology, University of North Carolina at Chapel Hill, CB# 7572, Physicians Office Building Rm# B105, Chapel Hill, NC, 27599, USA. amaja@email.unc.edu.
  • 6 Division of Gynecologic Oncology, University of North Carolina at Chapel Hill, CB# 7572, Physicians Office Building Rm# B105, Chapel Hill, NC, 27599, USA. jekilgor@email.unc.edu.
  • 7 Division of Gynecologic Oncology, University of North Carolina at Chapel Hill, CB# 7572, Physicians Office Building Rm# B105, Chapel Hill, NC, 27599, USA. Jessica.Stine@unchealth.unc.edu.
  • 8 Division of Gynecologic Oncology, University of North Carolina at Chapel Hill, CB# 7572, Physicians Office Building Rm# B105, Chapel Hill, NC, 27599, USA. monica_schointuch@med.unc.edu.
  • 9 Division of Gynecologic Oncology, University of North Carolina at Chapel Hill, CB# 7572, Physicians Office Building Rm# B105, Chapel Hill, NC, 27599, USA. Chunxiao_zhou@med.unc.edu.
  • 10 Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Chunxiao_zhou@med.unc.edu.
  • 11 Division of Gynecologic Oncology, University of North Carolina at Chapel Hill, CB# 7572, Physicians Office Building Rm# B105, Chapel Hill, NC, 27599, USA. victoria_baejump@med.unc.edu.
  • 12 Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. victoria_baejump@med.unc.edu.
PMID: 25631326 DOI: 10.1186/s13045-014-0097-x
Abstract

High rates of aerobic glycolysis represent a key mechanism by which endometrial Cancer cells consume glucose as its primary energy source. The up-regulated glycolytic pathway is a common therapeutic target whose inhibition has implications for anti-tumor activity in Cancer cells. The present study was aimed at evaluating the potential of a novel Lactate Dehydrogenase (LDH) inhibitor, Galloflavin, as a therapeutic agent for endometrial Cancer. Our results revealed that Galloflavin effectively inhibited cell growth in endometrial Cancer cell lines and primary cultures of human endometrial Cancer through its involvement in multiple signaling pathways that regulate metabolism, cell cycle, Apoptosis, cell stress and metastasis.

Figures
Products